 BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 GLOBE NEWSWIRE -- Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the publication of a paper detailing full results from a phase 2a study of GB0139 in Idiopathic Pulmonary Fibrosis IPF in the peer-reviewed publication European Respiratory Journal. 